SARS-CoV-2 mRNA vaccine injection site pseudolymphoma.
作者信息
Mintoff D, Scerri L, Betts A
机构信息
Department of Dermatology, Mater Dei Hospital, Msida, Malta.
Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.
出版信息
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e20-e22. doi: 10.1111/jdv.17680. Epub 2021 Sep 30.
Abstract
摘要
相似文献
1
SARS-CoV-2 mRNA vaccine injection site pseudolymphoma.严重急性呼吸综合征冠状病毒2型信使核糖核酸疫苗注射部位假淋巴瘤
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e20-e22. doi: 10.1111/jdv.17680. Epub 2021 Sep 30.
2
Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.肾移植受者中mRNA-1273和BNT162b2新冠病毒mRNA疫苗免疫原性的比较
Transpl Int. 2022 Jan 4;35:10026. doi: 10.3389/ti.2021.10026. eCollection 2021.
3
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
4
Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.SARS-CoV-2 mRNA 和重组蛋白候选疫苗引起的免疫反应比较。
Front Immunol. 2022 May 19;13:906457. doi: 10.3389/fimmu.2022.906457. eCollection 2022.
5
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults.基于RBD的新型冠状病毒mRNA疫苗异源加强免疫在中国成年人中的安全性和卓越免疫原性
Cell Res. 2022 Aug;32(8):777-780. doi: 10.1038/s41422-022-00681-3. Epub 2022 Jun 14.
6
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.在首次发生免疫性血小板减少性紫癜后成功进行mRNA SARS-CoV-2疫苗再次接种。
Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.
7
Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions: A Real-World Analysis.慢性疾病中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）mRNA疫苗抗体反应受损：一项真实世界分析
Chest. 2022 Jun;161(6):1490-1493. doi: 10.1016/j.chest.2021.12.654. Epub 2022 Jan 10.
8
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
9
Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?血液透析患者对 SARS-CoV-2 疫苗的抗体反应：灭活疫苗有效吗？
Ther Apher Dial. 2022 Aug;26(4):769-774. doi: 10.1111/1744-9987.13752. Epub 2021 Nov 16.
10
Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.接种 2 剂 BNT162b2 mRNA 疫苗后与抗 SARS-CoV-2 抗体水平相关的人口统计学和临床因素。
JAMA Netw Open. 2022 May 2;5(5):e2212996. doi: 10.1001/jamanetworkopen.2022.12996.
引用本文的文献
1
Cutaneous Pseudolymphoma after COVID-19 Vaccine Injection.新冠疫苗注射后出现的皮肤假性淋巴瘤。
Indian J Dermatol. 2024 May-Jun;69(3):269-272. doi: 10.4103/ijd.ijd_420_22. Epub 2024 Jun 26.
2
Primary Cutaneous CD4 Small/Medium T-Cell Lymphoproliferative Disorder Following COVID-19 Vaccination-What Do We Know about Lymphoproliferative Disorders and Cutaneous Lymphomas after COVID-19 Vaccination? A Report of an Atypical Case and a Review of the Literature.新冠疫苗接种后原发性皮肤CD4小/中型T细胞淋巴增殖性疾病——关于新冠疫苗接种后淋巴增殖性疾病和皮肤淋巴瘤我们了解多少？1例非典型病例报告及文献综述
Life (Basel). 2024 Mar 14;14(3):386. doi: 10.3390/life14030386.
3
Cutaneous B-cell Pseudolymphoma: A Rare Case Masquerading a Thoracic Mass in a Fourteen-Year-Old Male Patient.皮肤B细胞假性淋巴瘤：一例14岁男性患者伪装成胸部肿块的罕见病例。
Cureus. 2023 Apr 23;15(4):e38003. doi: 10.7759/cureus.38003. eCollection 2023 Apr.
4
Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.新冠病毒疫苗接种后皮肤不良反应的全球流行率和临床表现：系统评价和荟萃分析。
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1947-1968. doi: 10.1111/jdv.18294. Epub 2022 Jun 21.
5
SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.SARS-CoV-2 疫苗相关皮肤表现：系统综述。
Int J Dermatol. 2022 Oct;61(10):1187-1204. doi: 10.1111/ijd.16063. Epub 2022 Feb 9.
本文引用的文献
1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
2
Cutaneous pseudolymphoma following quadrivalent human papillomavirus vaccination - a rare adverse event.四价人乳头瘤病毒疫苗接种后发生的皮肤假性淋巴瘤——一种罕见的不良事件。
J Dtsch Dermatol Ges. 2018 Apr;16(4):465-467. doi: 10.1111/ddg.13470. Epub 2018 Mar 9.
3
Cutaneous B-cell pseudolymphoma at the site of vaccination.接种部位的皮肤B细胞假性淋巴瘤
Am J Dermatopathol. 2007 Dec;29(6):538-42. doi: 10.1097/DAD.0b013e3181591bea.
4
Vaccination-induced cutaneous pseudolymphoma.疫苗接种引起的皮肤假性淋巴瘤。
J Am Acad Dermatol. 2005 Apr;52(4):623-9. doi: 10.1016/j.jaad.2004.12.021.
Zotero 插件